Beyond TRUFORMA(TM), Zomedica's pipeline of products includes four therapeutics that are targeting treatment opportunities for some of the most common disorders in pets and include two formulations of metronidazole for diarrhea, methimazole for hyperthyroidism, and transdermal fluoxetine for behavioral problems.
All 30 patients were in hyperthyroidism state when the surgical option was planned, and they were undergone total thyroidectomy in a state of clinical or biological euthyroidism after medical therapy like antithyroid medications (Methimazole) and also received propranolol for control of cardiac associated thyrotoxic symptoms.
Zomedica initiated enrollment in its pilot efficacy study at the University of Georgia College of Veterinary Medicine to evaluate ZM-006, a transdermal methimazole formulation for the treatment of chronic hyperthyroidism in cats.
Medications such asTapazole (methimazole) and propylthiouracil (PTU) can reduce hormone production, but they can cause liver damage and are only used in patients who cannot have the other treatment options.
She had a history of Graves disease with a multinodular goiter involving the thyroid gland and had been receiving medical treatment with methimazole. On physical examination, a hard, protruding mass was noted in the anterior neck over the right thyroid cartilage.